PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
Breast cancer
Gene expression assay
HIV
Intrinsic subtypes
Risk of Recurrence score
Survival
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
15
03
2023
accepted:
03
05
2023
medline:
29
6
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and determining optimal treatment for individual patients. We studied the association of breast cancer survival with the PAM50 gene expression assay in HIV-positive and HIV-negative patients. RNA was extracted from formalin-fixed paraffin-embedded specimens of histologically confirmed invasive carcinoma and was purified using the AllPrep® DNA/RNA FFPE kit, Qiagen (Hilden, Germany). The NanoString RUO PAM50 algorithm was used to determine the molecular subtype and the risk of recurrence score of each sample. The overall and disease-free survival were determined with comparison made among HIV-positive and -negative patients. We then generated Kaplan-Meier survival curves, calculated p-values and estimated hazard ratios and their 95% confidence intervals using Cox regression models. Of the 384 RNA samples analysed, 98.4% met the required RNA quality standard and the specified QC threshold for the test. Luminal B was the most common PAM50 intrinsic subtype and 82.1% of patients were at high risk for disease recurrence based on ROR score. HIV infection, PAM50-based HER2-enriched and basal-like intrinsic subtypes, and high ROR were associated with poor overall and disease-free survival. HIV-positive patients with luminal A & B subtypes had significantly worse survival outcomes than HIV-negative luminal patents. Aggressive tumour biology was common in our cohort. HIV infection, PAM50 HER2-enriched,basal-like intrinsic subtypes and high ROR score were associated with poor overall and disease-free survival. HIV infection impacted survival in patients with luminal subtypes only.
Identifiants
pubmed: 37266756
doi: 10.1007/s10549-023-06969-1
pii: 10.1007/s10549-023-06969-1
pmc: PMC10300149
doi:
Substances chimiques
RNA
63231-63-0
Receptor, ErbB-2
EC 2.7.10.1
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337-346Subventions
Organisme : NCI NIH HHS
ID : R01 CA192627
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250012
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA094061
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA094061
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Int J Cancer. 2019 Mar 15;144(6):1251-1261
pubmed: 30367449
Q J Nucl Med Mol Imaging. 2013 Dec;57(4):312-21
pubmed: 24322788
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1027-1033
pubmed: 28619832
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Breast Cancer Res Treat. 2023 May;199(1):1-12
pubmed: 36867282
Cancer. 2012 Nov 15;118(22):5463-72
pubmed: 22544643
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
Am J Clin Oncol. 2014 Aug;37(4):404-10
pubmed: 24853663
J Clin Oncol. 2015 Jul 20;33(21):2376-83
pubmed: 26077242
Cancer. 2019 Aug 15;125(16):2868-2876
pubmed: 31050361
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
Clin Cancer Res. 2010 Dec 15;16(24):6100-10
pubmed: 21169259
Breast. 2013 Aug;22(4):525-31
pubmed: 23352568
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Breast Cancer Res. 2017 Nov 14;19(1):120
pubmed: 29137653
Breast Cancer Res Treat. 2021 Aug;189(1):285-296
pubmed: 34125339
S Afr Med J. 2017 Jun 30;107(7):595-601
pubmed: 29025449
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Ecancermedicalscience. 2021 Sep 07;15:1282
pubmed: 34824605
Breast Cancer Res Treat. 2009 May;115(2):423-8
pubmed: 18543098
BMC Med Genomics. 2015 Aug 22;8:54
pubmed: 26297356
BMC Cancer. 2014 Mar 13;14:177
pubmed: 24625003
PLoS One. 2018 Feb 2;13(2):e0192071
pubmed: 29394271
Breast Cancer Res Treat. 2023 Feb;197(3):647-659
pubmed: 36538247
Oncologist. 2015 Jul;20(7):780-8
pubmed: 26032138
JAMA. 2015 Jan 13;313(2):165-73
pubmed: 25585328
J Clin Oncol. 2013 Aug 1;31(22):2783-90
pubmed: 23816962
ESMO Open. 2020 Oct;5(5):e000829
pubmed: 33020218
Clin Cancer Res. 2010 Nov 1;16(21):5222-32
pubmed: 20837693
Int J Cancer. 2022 Jul 15;151(2):209-221
pubmed: 35218568
Breast. 2021 Oct;59:27-36
pubmed: 34126376
Ann Oncol. 2014 Feb;25(2):339-45
pubmed: 24347518
Pharmacogenomics J. 2020 Feb;20(1):27-46
pubmed: 31130722
Cancer Epidemiol. 2018 Feb;52:120-127
pubmed: 29306221
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Am J Pathol. 2017 Oct;187(10):2152-2162
pubmed: 28733194
Breast Cancer Res Treat. 2013 Jul;140(1):177-86
pubmed: 23801159
Breast. 2019 Feb;43:123-129
pubmed: 30550925